BassieNL schreef op 12 november 2021 13:21:
[...]Study data for
RonapreveA main study involving patients with COVID-19 who did not require oxygen and were at increased risk of their illness becoming severe showed that treatment with Ronapreve at the approved dose led to fewer hospitalisations or deaths when compared with placebo (dummy treatment). Overall 0.9% of patients treated with Ronapreve (11 out of
1,192 patients) were hospitalised or died within 29 days of treatment compared with 3.4% of patients on placebo (40 out of
1,193 patients).
Study data for
RegkironaA main study in patients with COVID-19 showed that Regkirona treatment led to fewer patients requiring hospitalisations or oxygen therapy or dying when compared with placebo. Among the patients at increased risk of their illness becoming severe, 3.1% of patients treated with Regkirona (14 out
446) were hospitalised, required supplemental oxygen or died within 28 days of treatment compared with 11.1% of patients on placebo (48 out of
434).
De Covid pilot study van Pharming in de VS:
32 patienten onderzocht